214 related articles for article (PubMed ID: 30395632)
1. Towards non-invasive characterisation of coronary stent re-endothelialisation - An in-vitro, electrical impedance study.
Holland I; McCormick C; Connolly P
PLoS One; 2018; 13(11):e0206758. PubMed ID: 30395632
[TBL] [Abstract][Full Text] [Related]
2. Activation of Peroxisome Proliferator-Activated Receptor-δ as Novel Therapeutic Strategy to Prevent In-Stent Restenosis and Stent Thrombosis.
Hytönen J; Leppänen O; Braesen JH; Schunck WH; Mueller D; Jung F; Mrowietz C; Jastroch M; von Bergwelt-Baildon M; Kappert K; Heuser A; Drenckhahn JD; Pieske B; Thierfelder L; Ylä-Herttuala S; Blaschke F
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1534-48. PubMed ID: 27283742
[TBL] [Abstract][Full Text] [Related]
3. Towards a self-reporting coronary artery stent--measuring neointimal growth associated with in-stent restenosis using electrical impedance techniques.
Shedden L; Kennedy S; Wadsworth R; Connolly P
Biosens Bioelectron; 2010 Oct; 26(2):661-6. PubMed ID: 20667708
[TBL] [Abstract][Full Text] [Related]
4. In vitro evaluation of vascular endothelial growth factor (VEGF)-eluting stents.
Swanson N; Hogrefe K; Javed Q; Gershlick AH
Int J Cardiol; 2003 Dec; 92(2-3):247-51. PubMed ID: 14659860
[TBL] [Abstract][Full Text] [Related]
5. Effect of a novel peptide, WKYMVm- and sirolimus-coated stent on re-endothelialization and anti-restenosis.
Jang EJ; Bae IH; Park DS; Lee SY; Lim KS; Park JK; Shim JW; Sim DS; Jeong MH
J Mater Sci Mater Med; 2015 Oct; 26(10):251. PubMed ID: 26438653
[TBL] [Abstract][Full Text] [Related]
6. Deficiency of MAPK-activated protein kinase 2 (MK2) prevents adverse remodelling and promotes endothelial healing after arterial injury.
Kapopara PR; von Felden J; Soehnlein O; Wang Y; Napp LC; Sonnenschein K; Wollert KC; Schieffer B; Gaestel M; Bauersachs J; Bavendiek U
Thromb Haemost; 2014 Dec; 112(6):1264-76. PubMed ID: 25120198
[TBL] [Abstract][Full Text] [Related]
7. Chronic impedance spectroscopy of an endovascular stent-electrode array.
Opie NL; John SE; Rind GS; Ronayne SM; Grayden DB; Burkitt AN; May CN; O'Brien TJ; Oxley TJ
J Neural Eng; 2016 Aug; 13(4):046020. PubMed ID: 27378157
[TBL] [Abstract][Full Text] [Related]
8. Surface engineering of cardiovascular stent with endothelial cell selectivity for in vivo re-endothelialisation.
Wei Y; Ji Y; Xiao LL; Lin QK; Xu JP; Ren KF; Ji J
Biomaterials; 2013 Apr; 34(11):2588-99. PubMed ID: 23352039
[TBL] [Abstract][Full Text] [Related]
9. The effects of stenting on coronary endothelium from a molecular biological view: Time for improvement?
Cornelissen A; Vogt FJ
J Cell Mol Med; 2019 Jan; 23(1):39-46. PubMed ID: 30353645
[TBL] [Abstract][Full Text] [Related]
10. New stent surface materials: the impact of polymer-dependent interactions of human endothelial cells, smooth muscle cells, and platelets.
Busch R; Strohbach A; Rethfeldt S; Walz S; Busch M; Petersen S; Felix S; Sternberg K
Acta Biomater; 2014 Feb; 10(2):688-700. PubMed ID: 24148751
[TBL] [Abstract][Full Text] [Related]
11. A TRPC3 blocker, ethyl-1-(4-(2,3,3-trichloroacrylamide)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate (Pyr3), prevents stent-induced arterial remodeling.
Koenig S; Schernthaner M; Maechler H; Kappe CO; Glasnov TN; Hoefler G; Braune M; Wittchow E; Groschner K
J Pharmacol Exp Ther; 2013 Jan; 344(1):33-40. PubMed ID: 23010361
[TBL] [Abstract][Full Text] [Related]
12. Targeting connexin 43 prevents platelet-derived growth factor-BB-induced phenotypic change in porcine coronary artery smooth muscle cells.
Chadjichristos CE; Morel S; Derouette JP; Sutter E; Roth I; Brisset AC; Bochaton-Piallat ML; Kwak BR
Circ Res; 2008 Mar; 102(6):653-60. PubMed ID: 18239136
[TBL] [Abstract][Full Text] [Related]
13. Stent coated with antibody against vascular endothelial-cadherin captures endothelial progenitor cells, accelerates re-endothelialization, and reduces neointimal formation.
Lim WH; Seo WW; Choe W; Kang CK; Park J; Cho HJ; Kyeong S; Hur J; Yang HM; Cho HJ; Lee YS; Kim HS
Arterioscler Thromb Vasc Biol; 2011 Dec; 31(12):2798-805. PubMed ID: 22015656
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of endothelialisation of coronary stents by laser surface engineering.
Li L; Mirhosseini N; Michael A; Liu Z; Wang T
Lasers Surg Med; 2013 Nov; 45(9):608-16. PubMed ID: 24037969
[TBL] [Abstract][Full Text] [Related]
15. Impact of parallel micro-engineered stent grooves on endothelial cell migration, proliferation, and function: an in vivo correlation study of the healing response in the coronary swine model.
Sprague EA; Tio F; Ahmed SH; Granada JF; Bailey SR
Circ Cardiovasc Interv; 2012 Aug; 5(4):499-507. PubMed ID: 22763346
[TBL] [Abstract][Full Text] [Related]
16. Endothelial function rather than endothelial restoration is altered in paclitaxel- as compared to bare metal-, sirolimusand tacrolimus-eluting stents.
van Beusekom HM; Sorop O; van den Heuvel M; Onuma Y; Duncker DJ; Danser AH; van der Giessen WJ
EuroIntervention; 2010 May; 6(1):117-25. PubMed ID: 20542807
[TBL] [Abstract][Full Text] [Related]
17. The Genous™ endothelial progenitor cell capture stent accelerates stent re-endothelialization but does not affect intimal hyperplasia in porcine coronary arteries.
van Beusekom HM; Ertaş G; Sorop O; Serruys PW; van der Giessen WJ
Catheter Cardiovasc Interv; 2012 Feb; 79(2):231-42. PubMed ID: 21834062
[TBL] [Abstract][Full Text] [Related]
18. Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform.
Jaschke B; Michaelis C; Milz S; Vogeser M; Mund T; Hengst L; Kastrati A; Schömig A; Wessely R
Cardiovasc Res; 2005 Dec; 68(3):483-92. PubMed ID: 16111664
[TBL] [Abstract][Full Text] [Related]
19. The role of mTOR inhibitors and HMG-CoA reductase inhibitors on young and old endothelial cell functions, critical for re-endothelialisation after percutaneous coronary intervention: an in vitro study.
Korybalska K; Kawka E; Breborowicz A; Witowski J
J Physiol Pharmacol; 2017 Jun; 68(3):397-405. PubMed ID: 28820396
[TBL] [Abstract][Full Text] [Related]
20. The CXCR4 antagonist POL5551 is equally effective as sirolimus in reducing neointima formation without impairing re-endothelialisation.
Hamesch K; Subramanian P; Li X; Dembowsky K; Chevalier E; Weber C; Schober A
Thromb Haemost; 2012 Feb; 107(2):356-68. PubMed ID: 22234341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
